Clinical Trial Update: A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial is evaluating Cadonilimab plus Regorafenib in patients with hepatocellular carcinoma who failed Camrelizumab plus Apatinib; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Cadonilimab
• Stivarga (regorafenib)

Snippet

Sponsor: Meng Chao Hepatobiliary Hospital of Fujian Medical University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING